ライフサイエンスコーパス: consolidation chemotherapy

1 d the benefit of cyclosporine (CsA) added to consolidation chemotherapy.

2 er ATRA maintenance or observation following consolidation chemotherapy.

3 who had been receiving radiation therapy and consolidation chemotherapy.

4 not after each of 4 cycles of induction and consolidation chemotherapy.

5 chemoradiation or chemoradiation followed by consolidation chemotherapy.

6 d for stage IIIA vs IIIB LA-NSCLC and use of consolidation chemotherapy.

7 l [CI], 18% to 42%) in patients receiving no consolidation chemotherapy, 22% (95% CI, 17% to 28%) in

8 importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular,

9 evaluated molecular response after induction/consolidation chemotherapy according to standardized met

10 /oxaliplatin CRT (50.4 Gy) or to group B for consolidation chemotherapy after CRT.

11 on chemotherapy or to receive four cycles of consolidation chemotherapy alone.

12 rally consistent with those of induction and consolidation chemotherapy alone.

13 The patient continued with consolidation chemotherapy and an autologous bone marrow

14 ib incorporated into intensive induction and consolidation chemotherapy, and as maintenance therapy f

15 vant chemotherapy with intrathecal thiotepa, consolidation chemotherapy, and autologous stem-cell res

16 erapy, autologous stem-cell transplantation, consolidation chemotherapy, and maintenance with interfe

17 therapy group) or short-course radiotherapy, consolidation chemotherapy, and surgery (total neoadjuva

18 rred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted.

19 ogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent

20 arm, and patients in this arm received less consolidation chemotherapy as a result of higher inducti

21 rectal cancer to receive either induction or consolidation chemotherapy as part of TNT.

22 ese data support induction LCCRT followed by consolidation chemotherapy as the preferred TNT regimen

23 s bone marrow transplantation with intensive consolidation chemotherapy as treatments for children wi

24 Induction and consolidation chemotherapy, as well as radiation dose, c

25 The value of administering consolidation chemotherapy before human leukocyte antige

26 rs administered after induction and possibly consolidation chemotherapy can shorten the duration of n

27 ompared randomized assignment with intensive consolidation chemotherapy (CC) or autologous bone marro

28 TNT in which CRT was followed by consolidation chemotherapy (CNCT) was the least costly a

29 signed 2:1 to receive standard induction and consolidation chemotherapy combined with either quizarti

30 and safety of bortezomib in combination with consolidation chemotherapy consisting of intermediate-do

31 stable disease received two 21-day cycles of consolidation chemotherapy consisting of paclitaxel 200

32 Both groups received consolidation chemotherapy consisting of vincristine and

33 (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and either total m

34 ion (INCT-CRT) or chemoradiation followed by consolidation chemotherapy (CRT-CNCT).

35 ely); 92% versus 85% completed all induction/consolidation chemotherapy cycles, respectively.

36 uction and in 27 (71%) of 38 patients during consolidation chemotherapy cycles.

37 ith high-dose DAT and the addition of CsA to consolidation chemotherapy did not prolong the durations

38 At relapse, intensive consolidation chemotherapy followed by stem cell transpl

39 rved in more patients in the blinatumomab vs consolidation chemotherapy group (90% [44/49] vs 54% [26

40 In the blinatumomab vs consolidation chemotherapy group, the incidence of serio

41 the blinatumomab group and 16 (29.6%) in the consolidation chemotherapy group.

42 e incidence of events in the blinatumomab vs consolidation chemotherapy groups was 31% vs 57% (log-ra

43 Phase II studies of induction or consolidation chemotherapy have also shown promise but t

44 Radiation dose-escalation and consolidation chemotherapy have been associated with inc

45 The addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-nega

46 with superior overall survival compared with consolidation chemotherapy in patients 60 years or young

47 sting the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients

48 Dose-escalation and consolidation chemotherapy leads to increased long-term

49 patients in first remission after intensive consolidation chemotherapy might prevent relapse.

50 tanea tarda was admitted to the hospital for consolidation chemotherapy of his leukemia.

51 of 254 patients who completed induction and consolidation chemotherapy on CALGB 9720 were randomly a

52 e/cytarabine combination, followed by either consolidation chemotherapy or allogeneic stem cell trans

53 est in evaluating the role of maintenance or consolidation chemotherapy or both.

54 IMD relapse during subsequent reinduction or consolidation chemotherapy or graft versus host disease

55 est radiotherapy (60-63 Gy), with or without consolidation chemotherapy or the same treatment plus me

56 f blinatumomab in addition to four cycles of consolidation chemotherapy or to receive four cycles of

57 %) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (P = .001).

58 5% CI, 5%-19%) and 2% (95% CI, 0%-11%) after consolidation chemotherapy (P = .005).

59 logeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (P = .22).

60 induced CR (P =.018) and at first test after consolidation chemotherapy (P =.037).

61 After consolidation chemotherapy, patients with NQ exceeding 1

62 equate response to OEPA and whether modified consolidation chemotherapy reduces gonadotoxicity.

63 teritinib incorporated into an induction and consolidation chemotherapy regimen, and as single-agent

64 , long-course chemoradiotherapy (L-CRT) plus consolidation chemotherapy (relative risk [RR], 1.96; 95

65 ring 3-year disease-free survival, S-RT plus consolidation chemotherapy (RR, 1.08; 95% CI, 1.01-1.14)

66 ar locoregional recurrence rate of S-RT plus consolidation chemotherapy (RR, 1.65; 95% CI, 1.03-2.63)

67 3.06), short-course radiotherapy (S-RT) plus consolidation chemotherapy (RR, 1.76; 95% CI, 1.34-2.30)

68 2 weeks after chemoradiation, two cycles of consolidation chemotherapy separated by 3 weeks were giv

69 2 and Total Therapy 3 that applied post-HDT consolidation chemotherapy (suggesting possible post-HDT

70 Remitting patients received one course of consolidation chemotherapy that included DNR with or wit

71 ection, postoperative radiation therapy, and consolidation chemotherapy (three courses of cyclophosph

72 The addition of induction or consolidation chemotherapy to standard neoadjuvant chemo

73 The most common adverse reaction during consolidation chemotherapy was grade III neutropenia in

74 nts with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time

75 first complete remission after induction and consolidation chemotherapy were randomly assigned to no

76 Of 37 children who received consolidation chemotherapy with ABMR, 15 are free of dis

77 as a slightly higher death rate in CR during consolidation chemotherapy with ADE (9%) than with DAT (

78 remission (CR) received up to two courses of consolidation chemotherapy with cytarabine 2 gm/m(2) on

79 Responding patients received consolidation chemotherapy with DNR pharmacokinetics per

80 Postremission consolidation chemotherapy with either placebo or PEG-rH

81 Chemoradiation and consolidation chemotherapy with or without metformin.